Drug profile

The FDA adverse-event record for Anti Inflammatory

14 FDA reports name Anti Inflammatory, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2139 of 2,679
by report volume (all drugs)
14
adverse-event reports
21.4%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Anti Inflammatory ranks #2133 of 2679 by total reports (14). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2133
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Anti Inflammatory has 14 reports now versus 10 in that prior snapshot: 4 more (40.0%).

Report change
+4
Death-coded reports
+1
Death-coded share
+1.4 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Anti Inflammatory changes

Signature read: 14 reports place Anti Inflammatory in the lower third of FDA AER volume (#2139 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
14
Total Reports
3
Deaths Reported
21.4%
Death-coded share of reports

Active Ingredients

Anti Inflammatory

Administration Routes

OralUnknownSubcutaneous

Species Affected

Dog 12
Cat 2

Most Affected Breeds

Domestic Shorthair 2
Crossbred Canine/dog 2
Great Pyrenees 1
Pug 1
Saint Bernard Dog 1
Terrier - Bull - American Pit 1
Sheepdog (unspecified) 1
Chihuahua 1
Bichon Frise 1
Weimaraner 1

Most Reported Reactions

Decreased activity 3
Unable to walk 2
Ataxia 2
Death by euthanasia 2
Urinary incontinence 2
Lethargy (see also Central nervous system depression in Neurological) 2
Joint pain 2
Seizure NOS 1
Hypersalivation 1
Emesis (multiple) 1
Vocalisation 1
Blistering (see also Application site SOC) 1

Outcome Breakdown

Ongoing
6 (42.9%)
Recovered/Normal
4 (28.6%)
Euthanized
2 (14.3%)
Outcome Unknown
1 (7.1%)
Died
1 (7.1%)

Anti Inflammatory: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Anti Inflammatory (#2139 of 2,679 by report volume); death-coded 21.4%. PlainBreed drug row · report volume stamp 14 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →